JP2007505157A - ＣＮＳ髄鞘再形成を促進する組換えヒトｍＡｂを含む組成物および方法 - Google Patents

ＣＮＳ髄鞘再形成を促進する組換えヒトｍＡｂを含む組成物および方法 Download PDF

Info

Publication number
JP2007505157A
JP2007505157A JP2006533147A JP2006533147A JP2007505157A JP 2007505157 A JP2007505157 A JP 2007505157A JP 2006533147 A JP2006533147 A JP 2006533147A JP 2006533147 A JP2006533147 A JP 2006533147A JP 2007505157 A JP2007505157 A JP 2007505157A
Authority
JP
Japan
Prior art keywords
antibody
administration
antibodies
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533147A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007505157A5 (enExample
Inventor
エリオット エー． グルスキン，
エリック コジュニッキ，
アーサー イー． ウォリントン，
アラン ジェイ． ビーバー，
モーゼス ロドリゲス，
Original Assignee
マヨ ファウンデイション フォア メディカル エデュケイション アンド リサーチ
アコルダ セラピューティックス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マヨ ファウンデイション フォア メディカル エデュケイション アンド リサーチ, アコルダ セラピューティックス filed Critical マヨ ファウンデイション フォア メディカル エデュケイション アンド リサーチ
Publication of JP2007505157A publication Critical patent/JP2007505157A/ja
Publication of JP2007505157A5 publication Critical patent/JP2007505157A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006533147A 2003-05-16 2004-05-17 ＣＮＳ髄鞘再形成を促進する組換えヒトｍＡｂを含む組成物および方法 Pending JP2007505157A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47123503P 2003-05-16 2003-05-16
PCT/US2004/015436 WO2004110355A2 (en) 2003-05-16 2004-05-17 Compositions and methods including a recombinant human mab that promotes cns remyelination

Publications (2)

Publication Number Publication Date
JP2007505157A true JP2007505157A (ja) 2007-03-08
JP2007505157A5 JP2007505157A5 (enExample) 2007-10-25

Family

ID=33551425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533147A Pending JP2007505157A (ja) 2003-05-16 2004-05-17 ＣＮＳ髄鞘再形成を促進する組換えヒトｍＡｂを含む組成物および方法

Country Status (8)

Country Link
US (5) US8460665B2 (enExample)
EP (1) EP1648427B1 (enExample)
JP (1) JP2007505157A (enExample)
AU (2) AU2004247021A1 (enExample)
CA (2) CA2525917C (enExample)
ES (1) ES2451993T3 (enExample)
PL (1) PL1648427T3 (enExample)
WO (1) WO2004110355A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014504263A (ja) * 2010-10-19 2014-02-20 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ ヒト抗体ならびに神経疾患の処置のためのその診断的および治療的使用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509235A (ja) * 2006-11-03 2010-03-25 ノースウェスタン ユニバーシティ 多発性硬化症の治療
WO2009104100A2 (en) * 2008-02-19 2009-08-27 Patrys Limited Antibody combinations, and methods of making and using same
WO2012149024A2 (en) 2011-04-28 2012-11-01 Mayo Foundation For Medical Education And Research Dna aptamers for promoting remyelination
BR112014025898A2 (pt) 2012-04-17 2017-11-07 Mayo Found Medical Education & Res anticorpos humanos e sequências de ligação específica, para uso em acidente vascular cerebral e isquemia ou condições isquêmicas
WO2016073963A1 (en) 2014-11-07 2016-05-12 Mayo Foundation For Medical Education And Research Treatment of neonatal hypoxia including impairments or effects thereof
US11999778B2 (en) 2016-05-13 2024-06-04 The Board Of Regents Of The University Of Texas System VH4 antibodies and compositions comprising the same
EP3401682A1 (en) * 2017-05-09 2018-11-14 Université de Nantes Diagnosis, prevention and treatment of demyelinating disorders of the central nervous system
WO2020118218A1 (en) 2018-12-06 2020-06-11 Mayo Foundation For Medical Education And Research Short dna aptamers and methods for promoting remyelination

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085797A1 (en) * 2000-05-10 2001-11-15 Mayo Foundation For Medical Education & Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
JP2008127346A (ja) 2006-11-22 2008-06-05 Toshitsu Kagaku Kenkyusho:Kk 自己免疫疾患、炎症および神経疾患を治療および予防するための医薬

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
FR2556219B1 (fr) * 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
DE3825429C2 (de) 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US5256771A (en) 1990-04-03 1993-10-26 Miles Inc. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
US5591629A (en) * 1994-04-29 1997-01-07 Mayo Foundation For Medical Education & Research Monoclonal antibodies which promote central nervous system remyelination
US7473423B2 (en) * 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085797A1 (en) * 2000-05-10 2001-11-15 Mayo Foundation For Medical Education & Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
JP2008127346A (ja) 2006-11-22 2008-06-05 Toshitsu Kagaku Kenkyusho:Kk 自己免疫疾患、炎症および神経疾患を治療および予防するための医薬

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6010028002; 'Ｃｈｏｏｓｉｎｇ　ｄｒｕｇ　ｔｈｅｒａｐｙ　ｆｏｒ　ｍｕｌｔｉｐｌｅ　ｓｃｌｅｒｏｓｉｓ．　Ａｎ　ｕｐｄａｔｅ' Ｄｒｕｇｓ Ｖｏｌ．５６，　Ｎｏ．４, 1998, ｐ．５５５-６９ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014504263A (ja) * 2010-10-19 2014-02-20 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ ヒト抗体ならびに神経疾患の処置のためのその診断的および治療的使用

Also Published As

Publication number Publication date
CA2967294A1 (en) 2004-12-23
US20200247883A1 (en) 2020-08-06
EP1648427B1 (en) 2013-12-18
US8460665B2 (en) 2013-06-11
CA2525917A1 (en) 2004-12-23
PL1648427T3 (pl) 2014-05-30
AU2004247021A1 (en) 2004-12-23
CA2525917C (en) 2017-07-04
AU2010202111B2 (en) 2012-11-15
EP1648427A4 (en) 2007-04-11
ES2451993T3 (es) 2014-03-28
US20070086999A1 (en) 2007-04-19
US9751943B2 (en) 2017-09-05
CA2967294C (en) 2020-04-28
AU2010202111A1 (en) 2010-06-17
WO2004110355A3 (en) 2006-05-18
US20130309240A1 (en) 2013-11-21
US20180179277A1 (en) 2018-06-28
WO2004110355A2 (en) 2004-12-23
EP1648427A2 (en) 2006-04-26
US20150299316A1 (en) 2015-10-22
US8968735B2 (en) 2015-03-03

Similar Documents

Publication Publication Date Title
US20200247883A1 (en) Compositions and methods including a recombinant human mab that promotes cns remyelination
US10351620B2 (en) Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US20210093718A1 (en) Neutralizing anti-tl1a monoclonal antibodies
JP5795753B2 (ja) 髄鞘再形成を誘導する能力を有するヒトＩｇＭ抗体、および、特に中枢神経系における、その診断使用及び治療使用
US12324827B2 (en) Combination therapy for the treatment of migraines
HK1154605B (en) Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
HK1154604B (en) Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
HK1154605A (en) Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100823

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100922

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101022

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110623

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110719

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130118